Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 905711 in Advanced GI Cancers
NCT04137289Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2020
- Primary completion
- Jul 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 1, open-label trial of BI 905711 in gastrointestinal neoplasms, colorectal adenocarcinoma, gastric adenocarcinoma and 5 more (9 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose, Dose-Limiting Toxicities and 2 more. Started Mar 2020; status: completed.
02
Drugs
BI 905711
03
Conditions
gastrointestinal neoplasmscolorectal adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04137289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04137289.